nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—EGFR—urinary bladder cancer	0.423	1	CbGaD
Lidocaine—CYP2B6—Thiotepa—urinary bladder cancer	0.0616	0.194	CbGbCtD
Lidocaine—ABCB1—Mitomycin—urinary bladder cancer	0.0417	0.131	CbGbCtD
Lidocaine—CYP2A6—Fluorouracil—urinary bladder cancer	0.0307	0.0966	CbGbCtD
Lidocaine—CYP3A4—Thiotepa—urinary bladder cancer	0.0189	0.0595	CbGbCtD
Lidocaine—CYP2B6—Cisplatin—urinary bladder cancer	0.017	0.0534	CbGbCtD
Lidocaine—CYP2C8—Fluorouracil—urinary bladder cancer	0.0152	0.0476	CbGbCtD
Lidocaine—CYP3A5—Etoposide—urinary bladder cancer	0.0132	0.0413	CbGbCtD
Lidocaine—CYP2C8—Etoposide—urinary bladder cancer	0.0127	0.0397	CbGbCtD
Lidocaine—ABCB1—Gemcitabine—urinary bladder cancer	0.012	0.0377	CbGbCtD
Lidocaine—CYP1A2—Fluorouracil—urinary bladder cancer	0.0117	0.0369	CbGbCtD
Lidocaine—CYP2B6—Doxorubicin—urinary bladder cancer	0.0114	0.0358	CbGbCtD
Lidocaine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0106	0.0332	CbGbCtD
Lidocaine—CYP1A2—Etoposide—urinary bladder cancer	0.00979	0.0308	CbGbCtD
Lidocaine—CYP2C9—Cisplatin—urinary bladder cancer	0.00898	0.0282	CbGbCtD
Lidocaine—ABCB1—Cisplatin—urinary bladder cancer	0.00872	0.0274	CbGbCtD
Lidocaine—ABCB1—Etoposide—urinary bladder cancer	0.00856	0.0269	CbGbCtD
Lidocaine—ABCB1—Doxorubicin—urinary bladder cancer	0.00584	0.0184	CbGbCtD
Lidocaine—ABCB1—Methotrexate—urinary bladder cancer	0.00566	0.0178	CbGbCtD
Lidocaine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0055	0.0173	CbGbCtD
Lidocaine—CYP3A4—Etoposide—urinary bladder cancer	0.00513	0.0161	CbGbCtD
Lidocaine—CYP3A4—Doxorubicin—urinary bladder cancer	0.0035	0.011	CbGbCtD
Lidocaine—EGFR—prostate gland—urinary bladder cancer	0.00223	0.0639	CbGeAlD
Lidocaine—CYP1A2—urine—urinary bladder cancer	0.00187	0.0534	CbGeAlD
Lidocaine—SCN9A—prostate gland—urinary bladder cancer	0.00184	0.0526	CbGeAlD
Lidocaine—CYP2C9—urine—urinary bladder cancer	0.00177	0.0507	CbGeAlD
Lidocaine—SCN4A—prostate gland—urinary bladder cancer	0.00164	0.0469	CbGeAlD
Lidocaine—CYP3A4—urine—urinary bladder cancer	0.00135	0.0386	CbGeAlD
Lidocaine—CYP2D6—urine—urinary bladder cancer	0.00133	0.038	CbGeAlD
Lidocaine—SCN3A—prostate gland—urinary bladder cancer	0.00128	0.0365	CbGeAlD
Lidocaine—CYP2A6—prostate gland—urinary bladder cancer	0.00128	0.0365	CbGeAlD
Lidocaine—SCN4A—renal system—urinary bladder cancer	0.00112	0.032	CbGeAlD
Lidocaine—CYP2A6—seminal vesicle—urinary bladder cancer	0.00108	0.0308	CbGeAlD
Lidocaine—CYP2C18—vagina—urinary bladder cancer	0.000953	0.0272	CbGeAlD
Lidocaine—SCN3A—renal system—urinary bladder cancer	0.00087	0.0249	CbGeAlD
Lidocaine—SLC22A5—prostate gland—urinary bladder cancer	0.00074	0.0211	CbGeAlD
Lidocaine—SCN2A—vagina—urinary bladder cancer	0.000717	0.0205	CbGeAlD
Lidocaine—EGFR—lymph node—urinary bladder cancer	0.000714	0.0204	CbGeAlD
Lidocaine—SCN3A—female reproductive system—urinary bladder cancer	0.000697	0.0199	CbGeAlD
Lidocaine—CYP3A5—prostate gland—urinary bladder cancer	0.000647	0.0185	CbGeAlD
Lidocaine—SCN3A—vagina—urinary bladder cancer	0.00063	0.018	CbGeAlD
Lidocaine—CYP2A6—vagina—urinary bladder cancer	0.00063	0.018	CbGeAlD
Lidocaine—SCN5A—vagina—urinary bladder cancer	0.000629	0.018	CbGeAlD
Lidocaine—SLC22A5—seminal vesicle—urinary bladder cancer	0.000626	0.0179	CbGeAlD
Lidocaine—SCN9A—lymph node—urinary bladder cancer	0.000588	0.0168	CbGeAlD
Lidocaine—SLC22A5—renal system—urinary bladder cancer	0.000504	0.0144	CbGeAlD
Lidocaine—SLC22A5—urethra—urinary bladder cancer	0.000495	0.0142	CbGeAlD
Lidocaine—CYP2C8—renal system—urinary bladder cancer	0.000488	0.014	CbGeAlD
Lidocaine—CYP1A2—renal system—urinary bladder cancer	0.000457	0.0131	CbGeAlD
Lidocaine—SCN10A—lymph node—urinary bladder cancer	0.000447	0.0128	CbGeAlD
Lidocaine—CYP3A5—renal system—urinary bladder cancer	0.000441	0.0126	CbGeAlD
Lidocaine—CYP2B6—renal system—urinary bladder cancer	0.000438	0.0125	CbGeAlD
Lidocaine—SCN3A—lymph node—urinary bladder cancer	0.000408	0.0117	CbGeAlD
Lidocaine—SLC22A5—female reproductive system—urinary bladder cancer	0.000404	0.0115	CbGeAlD
Lidocaine—CYP2C8—female reproductive system—urinary bladder cancer	0.000391	0.0112	CbGeAlD
Lidocaine—SLC22A5—vagina—urinary bladder cancer	0.000365	0.0104	CbGeAlD
Lidocaine—CYP2C8—vagina—urinary bladder cancer	0.000354	0.0101	CbGeAlD
Lidocaine—CYP2B6—female reproductive system—urinary bladder cancer	0.000351	0.01	CbGeAlD
Lidocaine—CYP2C9—female reproductive system—urinary bladder cancer	0.000347	0.00993	CbGeAlD
Lidocaine—ABCB1—prostate gland—urinary bladder cancer	0.000343	0.00982	CbGeAlD
Lidocaine—CYP3A4—renal system—urinary bladder cancer	0.000331	0.00945	CbGeAlD
Lidocaine—CYP2D6—renal system—urinary bladder cancer	0.000325	0.0093	CbGeAlD
Lidocaine—CYP3A5—vagina—urinary bladder cancer	0.000319	0.00912	CbGeAlD
Lidocaine—CYP2B6—vagina—urinary bladder cancer	0.000317	0.00907	CbGeAlD
Lidocaine—ABCB1—seminal vesicle—urinary bladder cancer	0.00029	0.0083	CbGeAlD
Lidocaine—CYP3A4—female reproductive system—urinary bladder cancer	0.000265	0.00757	CbGeAlD
Lidocaine—CYP2D6—female reproductive system—urinary bladder cancer	0.000261	0.00745	CbGeAlD
Lidocaine—ABCB1—epithelium—urinary bladder cancer	0.000252	0.00721	CbGeAlD
Lidocaine—SLC22A5—lymph node—urinary bladder cancer	0.000236	0.00675	CbGeAlD
Lidocaine—ABCB1—renal system—urinary bladder cancer	0.000234	0.00669	CbGeAlD
Lidocaine—ABCB1—urethra—urinary bladder cancer	0.00023	0.00657	CbGeAlD
Lidocaine—ABCB1—female reproductive system—urinary bladder cancer	0.000187	0.00536	CbGeAlD
Lidocaine—Paraesthesia—Thiotepa—urinary bladder cancer	0.000175	0.00138	CcSEcCtD
Lidocaine—Hypertension—Gemcitabine—urinary bladder cancer	0.000174	0.00137	CcSEcCtD
Lidocaine—Somnolence—Thiotepa—urinary bladder cancer	0.000174	0.00137	CcSEcCtD
Lidocaine—Convulsion—Fluorouracil—urinary bladder cancer	0.000171	0.00135	CcSEcCtD
Lidocaine—Chest pain—Gemcitabine—urinary bladder cancer	0.000171	0.00135	CcSEcCtD
Lidocaine—Osteoarthritis—Methotrexate—urinary bladder cancer	0.000171	0.00135	CcSEcCtD
Lidocaine—ABCB1—vagina—urinary bladder cancer	0.00017	0.00485	CbGeAlD
Lidocaine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000169	0.00133	CcSEcCtD
Lidocaine—Chest pain—Fluorouracil—urinary bladder cancer	0.000169	0.00133	CcSEcCtD
Lidocaine—Dysgeusia—Etoposide—urinary bladder cancer	0.000168	0.00133	CcSEcCtD
Lidocaine—Dermatitis bullous—Epirubicin—urinary bladder cancer	0.000167	0.00132	CcSEcCtD
Lidocaine—Pain—Thiotepa—urinary bladder cancer	0.000167	0.00132	CcSEcCtD
Lidocaine—Back pain—Etoposide—urinary bladder cancer	0.000166	0.00131	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.000165	0.0013	CcSEcCtD
Lidocaine—Oedema—Gemcitabine—urinary bladder cancer	0.000164	0.0013	CcSEcCtD
Lidocaine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000164	0.0013	CcSEcCtD
Lidocaine—Confusional state—Fluorouracil—urinary bladder cancer	0.000163	0.00128	CcSEcCtD
Lidocaine—Convulsion—Cisplatin—urinary bladder cancer	0.000163	0.00128	CcSEcCtD
Lidocaine—Oedema—Fluorouracil—urinary bladder cancer	0.000162	0.00127	CcSEcCtD
Lidocaine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000162	0.00127	CcSEcCtD
Lidocaine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000161	0.00127	CcSEcCtD
Lidocaine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000161	0.00127	CcSEcCtD
Lidocaine—Osteoarthritis—Epirubicin—urinary bladder cancer	0.00016	0.00126	CcSEcCtD
Lidocaine—Diplopia—Epirubicin—urinary bladder cancer	0.00016	0.00126	CcSEcCtD
Lidocaine—Anxiety—Cisplatin—urinary bladder cancer	0.000159	0.00126	CcSEcCtD
Lidocaine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000159	0.00125	CcSEcCtD
Lidocaine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000158	0.00125	CcSEcCtD
Lidocaine—Urticaria—Thiotepa—urinary bladder cancer	0.000155	0.00122	CcSEcCtD
Lidocaine—Dermatitis bullous—Doxorubicin—urinary bladder cancer	0.000155	0.00122	CcSEcCtD
Lidocaine—Hypotension—Gemcitabine—urinary bladder cancer	0.000154	0.00121	CcSEcCtD
Lidocaine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000153	0.00121	CcSEcCtD
Lidocaine—Oedema—Cisplatin—urinary bladder cancer	0.000153	0.00121	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.000153	0.00121	CcSEcCtD
Lidocaine—Cardiac arrest—Epirubicin—urinary bladder cancer	0.000152	0.0012	CcSEcCtD
Lidocaine—Loss of consciousness—Etoposide—urinary bladder cancer	0.000151	0.00119	CcSEcCtD
Lidocaine—Hypotension—Fluorouracil—urinary bladder cancer	0.000151	0.00119	CcSEcCtD
Lidocaine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00015	0.00118	CcSEcCtD
Lidocaine—Convulsion—Etoposide—urinary bladder cancer	0.000149	0.00117	CcSEcCtD
Lidocaine—Hypertension—Etoposide—urinary bladder cancer	0.000148	0.00117	CcSEcCtD
Lidocaine—Osteoarthritis—Doxorubicin—urinary bladder cancer	0.000148	0.00117	CcSEcCtD
Lidocaine—Diplopia—Doxorubicin—urinary bladder cancer	0.000148	0.00117	CcSEcCtD
Lidocaine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000148	0.00117	CcSEcCtD
Lidocaine—Asthma—Methotrexate—urinary bladder cancer	0.000148	0.00117	CcSEcCtD
Lidocaine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000148	0.00116	CcSEcCtD
Lidocaine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000146	0.00115	CcSEcCtD
Lidocaine—Chest pain—Etoposide—urinary bladder cancer	0.000146	0.00115	CcSEcCtD
Lidocaine—Somnolence—Gemcitabine—urinary bladder cancer	0.000146	0.00115	CcSEcCtD
Lidocaine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000145	0.00114	CcSEcCtD
Lidocaine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000144	0.00114	CcSEcCtD
Lidocaine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000144	0.00113	CcSEcCtD
Lidocaine—Somnolence—Fluorouracil—urinary bladder cancer	0.000144	0.00113	CcSEcCtD
Lidocaine—Hypotension—Cisplatin—urinary bladder cancer	0.000143	0.00113	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000142	0.00112	CcSEcCtD
Lidocaine—Confusional state—Etoposide—urinary bladder cancer	0.000141	0.00112	CcSEcCtD
Lidocaine—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000141	0.00111	CcSEcCtD
Lidocaine—Pain—Gemcitabine—urinary bladder cancer	0.000141	0.00111	CcSEcCtD
Lidocaine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00014	0.00111	CcSEcCtD
Lidocaine—Asthenia—Thiotepa—urinary bladder cancer	0.00014	0.0011	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000139	0.0011	CcSEcCtD
Lidocaine—Asthma—Epirubicin—urinary bladder cancer	0.000138	0.00109	CcSEcCtD
Lidocaine—Dysphagia—Epirubicin—urinary bladder cancer	0.000138	0.00109	CcSEcCtD
Lidocaine—Pain—Fluorouracil—urinary bladder cancer	0.000138	0.00109	CcSEcCtD
Lidocaine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000138	0.00108	CcSEcCtD
Lidocaine—Dyspnoea—Cisplatin—urinary bladder cancer	0.000137	0.00108	CcSEcCtD
Lidocaine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000136	0.00107	CcSEcCtD
Lidocaine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000135	0.00107	CcSEcCtD
Lidocaine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000133	0.00105	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000132	0.00104	CcSEcCtD
Lidocaine—Drowsiness—Methotrexate—urinary bladder cancer	0.000132	0.00104	CcSEcCtD
Lidocaine—Hypotension—Etoposide—urinary bladder cancer	0.000131	0.00103	CcSEcCtD
Lidocaine—Pain—Cisplatin—urinary bladder cancer	0.000131	0.00103	CcSEcCtD
Lidocaine—Dizziness—Thiotepa—urinary bladder cancer	0.000129	0.00102	CcSEcCtD
Lidocaine—Stomatitis—Methotrexate—urinary bladder cancer	0.000128	0.00101	CcSEcCtD
Lidocaine—Urticaria—Fluorouracil—urinary bladder cancer	0.000128	0.00101	CcSEcCtD
Lidocaine—Asthma—Doxorubicin—urinary bladder cancer	0.000128	0.00101	CcSEcCtD
Lidocaine—Dysphagia—Doxorubicin—urinary bladder cancer	0.000128	0.00101	CcSEcCtD
Lidocaine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000126	0.000995	CcSEcCtD
Lidocaine—Paraesthesia—Etoposide—urinary bladder cancer	0.000126	0.000993	CcSEcCtD
Lidocaine—Dyspnoea—Etoposide—urinary bladder cancer	0.000125	0.000986	CcSEcCtD
Lidocaine—Somnolence—Etoposide—urinary bladder cancer	0.000125	0.000983	CcSEcCtD
Lidocaine—Vomiting—Thiotepa—urinary bladder cancer	0.000124	0.000979	CcSEcCtD
Lidocaine—Drowsiness—Epirubicin—urinary bladder cancer	0.000123	0.000972	CcSEcCtD
Lidocaine—Rash—Thiotepa—urinary bladder cancer	0.000123	0.000971	CcSEcCtD
Lidocaine—Dermatitis—Thiotepa—urinary bladder cancer	0.000123	0.00097	CcSEcCtD
Lidocaine—Headache—Thiotepa—urinary bladder cancer	0.000122	0.000965	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000121	0.000955	CcSEcCtD
Lidocaine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000121	0.000953	CcSEcCtD
Lidocaine—Stomatitis—Epirubicin—urinary bladder cancer	0.00012	0.000948	CcSEcCtD
Lidocaine—Pain—Etoposide—urinary bladder cancer	0.00012	0.000946	CcSEcCtD
Lidocaine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000119	0.000938	CcSEcCtD
Lidocaine—Haemoglobin—Methotrexate—urinary bladder cancer	0.000119	0.000937	CcSEcCtD
Lidocaine—Haemorrhage—Methotrexate—urinary bladder cancer	0.000118	0.000933	CcSEcCtD
Lidocaine—Asthenia—Gemcitabine—urinary bladder cancer	0.000118	0.000929	CcSEcCtD
Lidocaine—Nausea—Thiotepa—urinary bladder cancer	0.000116	0.000915	CcSEcCtD
Lidocaine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000116	0.000912	CcSEcCtD
Lidocaine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000114	0.0009	CcSEcCtD
Lidocaine—Visual impairment—Methotrexate—urinary bladder cancer	0.000114	0.000899	CcSEcCtD
Lidocaine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000113	0.00089	CcSEcCtD
Lidocaine—Bradycardia—Epirubicin—urinary bladder cancer	0.000113	0.000889	CcSEcCtD
Lidocaine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000112	0.000882	CcSEcCtD
Lidocaine—Urticaria—Etoposide—urinary bladder cancer	0.000111	0.000879	CcSEcCtD
Lidocaine—Haemoglobin—Epirubicin—urinary bladder cancer	0.000111	0.000877	CcSEcCtD
Lidocaine—Stomatitis—Doxorubicin—urinary bladder cancer	0.000111	0.000877	CcSEcCtD
Lidocaine—Rhinitis—Epirubicin—urinary bladder cancer	0.000111	0.000875	CcSEcCtD
Lidocaine—Haemorrhage—Epirubicin—urinary bladder cancer	0.000111	0.000873	CcSEcCtD
Lidocaine—Eye disorder—Methotrexate—urinary bladder cancer	0.000111	0.000872	CcSEcCtD
Lidocaine—Tinnitus—Methotrexate—urinary bladder cancer	0.00011	0.00087	CcSEcCtD
Lidocaine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.00011	0.000868	CcSEcCtD
Lidocaine—Asthenia—Cisplatin—urinary bladder cancer	0.00011	0.000866	CcSEcCtD
Lidocaine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.00011	0.000866	CcSEcCtD
Lidocaine—ABCB1—lymph node—urinary bladder cancer	0.00011	0.00313	CbGeAlD
Lidocaine—Angiopathy—Methotrexate—urinary bladder cancer	0.000107	0.000846	CcSEcCtD
Lidocaine—Immune system disorder—Methotrexate—urinary bladder cancer	0.000107	0.000842	CcSEcCtD
Lidocaine—Dizziness—Fluorouracil—urinary bladder cancer	0.000107	0.000842	CcSEcCtD
Lidocaine—Visual impairment—Epirubicin—urinary bladder cancer	0.000107	0.000841	CcSEcCtD
Lidocaine—Chills—Methotrexate—urinary bladder cancer	0.000106	0.000837	CcSEcCtD
Lidocaine—Vomiting—Gemcitabine—urinary bladder cancer	0.000104	0.000824	CcSEcCtD
Lidocaine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000104	0.000822	CcSEcCtD
Lidocaine—Rash—Gemcitabine—urinary bladder cancer	0.000104	0.000817	CcSEcCtD
Lidocaine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000103	0.000816	CcSEcCtD
Lidocaine—Eye disorder—Epirubicin—urinary bladder cancer	0.000103	0.000816	CcSEcCtD
Lidocaine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000103	0.000815	CcSEcCtD
Lidocaine—Tinnitus—Epirubicin—urinary bladder cancer	0.000103	0.000814	CcSEcCtD
Lidocaine—Erythema—Methotrexate—urinary bladder cancer	0.000103	0.000812	CcSEcCtD
Lidocaine—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000103	0.000812	CcSEcCtD
Lidocaine—Headache—Gemcitabine—urinary bladder cancer	0.000103	0.000812	CcSEcCtD
Lidocaine—Flushing—Epirubicin—urinary bladder cancer	0.000103	0.00081	CcSEcCtD
Lidocaine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000103	0.00081	CcSEcCtD
Lidocaine—Vomiting—Fluorouracil—urinary bladder cancer	0.000103	0.00081	CcSEcCtD
Lidocaine—Rhinitis—Doxorubicin—urinary bladder cancer	0.000103	0.00081	CcSEcCtD
Lidocaine—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000102	0.000808	CcSEcCtD
Lidocaine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000102	0.000804	CcSEcCtD
Lidocaine—Rash—Fluorouracil—urinary bladder cancer	0.000102	0.000803	CcSEcCtD
Lidocaine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000102	0.000802	CcSEcCtD
Lidocaine—Headache—Fluorouracil—urinary bladder cancer	0.000101	0.000798	CcSEcCtD
Lidocaine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000101	0.000795	CcSEcCtD
Lidocaine—Asthenia—Etoposide—urinary bladder cancer	0.000101	0.000794	CcSEcCtD
Lidocaine—Angiopathy—Epirubicin—urinary bladder cancer	0.0001	0.000792	CcSEcCtD
Lidocaine—Immune system disorder—Epirubicin—urinary bladder cancer	0.0001	0.000788	CcSEcCtD
Lidocaine—Back pain—Methotrexate—urinary bladder cancer	9.96e-05	0.000785	CcSEcCtD
Lidocaine—Chills—Epirubicin—urinary bladder cancer	9.93e-05	0.000783	CcSEcCtD
Lidocaine—Visual impairment—Doxorubicin—urinary bladder cancer	9.87e-05	0.000778	CcSEcCtD
Lidocaine—Nausea—Gemcitabine—urinary bladder cancer	9.76e-05	0.000769	CcSEcCtD
Lidocaine—Vomiting—Cisplatin—urinary bladder cancer	9.74e-05	0.000768	CcSEcCtD
Lidocaine—Vision blurred—Methotrexate—urinary bladder cancer	9.7e-05	0.000765	CcSEcCtD
Lidocaine—Rash—Cisplatin—urinary bladder cancer	9.66e-05	0.000761	CcSEcCtD
Lidocaine—Dermatitis—Cisplatin—urinary bladder cancer	9.65e-05	0.000761	CcSEcCtD
Lidocaine—Erythema—Epirubicin—urinary bladder cancer	9.64e-05	0.00076	CcSEcCtD
Lidocaine—Nausea—Fluorouracil—urinary bladder cancer	9.6e-05	0.000757	CcSEcCtD
Lidocaine—Eye disorder—Doxorubicin—urinary bladder cancer	9.57e-05	0.000755	CcSEcCtD
Lidocaine—Tinnitus—Doxorubicin—urinary bladder cancer	9.55e-05	0.000753	CcSEcCtD
Lidocaine—Cardiac disorder—Doxorubicin—urinary bladder cancer	9.51e-05	0.000749	CcSEcCtD
Lidocaine—Flushing—Doxorubicin—urinary bladder cancer	9.51e-05	0.000749	CcSEcCtD
Lidocaine—Tension—Epirubicin—urinary bladder cancer	9.46e-05	0.000746	CcSEcCtD
Lidocaine—Dysgeusia—Epirubicin—urinary bladder cancer	9.44e-05	0.000744	CcSEcCtD
Lidocaine—Nervousness—Epirubicin—urinary bladder cancer	9.36e-05	0.000738	CcSEcCtD
Lidocaine—Back pain—Epirubicin—urinary bladder cancer	9.32e-05	0.000735	CcSEcCtD
Lidocaine—Angiopathy—Doxorubicin—urinary bladder cancer	9.29e-05	0.000733	CcSEcCtD
Lidocaine—Dizziness—Etoposide—urinary bladder cancer	9.28e-05	0.000732	CcSEcCtD
Lidocaine—Immune system disorder—Doxorubicin—urinary bladder cancer	9.25e-05	0.000729	CcSEcCtD
Lidocaine—Chills—Doxorubicin—urinary bladder cancer	9.19e-05	0.000725	CcSEcCtD
Lidocaine—Nausea—Cisplatin—urinary bladder cancer	9.1e-05	0.000717	CcSEcCtD
Lidocaine—Vision blurred—Epirubicin—urinary bladder cancer	9.08e-05	0.000716	CcSEcCtD
Lidocaine—Convulsion—Methotrexate—urinary bladder cancer	8.92e-05	0.000703	CcSEcCtD
Lidocaine—Vomiting—Etoposide—urinary bladder cancer	8.92e-05	0.000703	CcSEcCtD
Lidocaine—Erythema—Doxorubicin—urinary bladder cancer	8.92e-05	0.000703	CcSEcCtD
Lidocaine—Agitation—Epirubicin—urinary bladder cancer	8.86e-05	0.000698	CcSEcCtD
Lidocaine—Rash—Etoposide—urinary bladder cancer	8.85e-05	0.000697	CcSEcCtD
Lidocaine—Dermatitis—Etoposide—urinary bladder cancer	8.84e-05	0.000697	CcSEcCtD
Lidocaine—Headache—Etoposide—urinary bladder cancer	8.79e-05	0.000693	CcSEcCtD
Lidocaine—Chest pain—Methotrexate—urinary bladder cancer	8.77e-05	0.000691	CcSEcCtD
Lidocaine—Tension—Doxorubicin—urinary bladder cancer	8.75e-05	0.00069	CcSEcCtD
Lidocaine—Dysgeusia—Doxorubicin—urinary bladder cancer	8.73e-05	0.000688	CcSEcCtD
Lidocaine—Nervousness—Doxorubicin—urinary bladder cancer	8.66e-05	0.000683	CcSEcCtD
Lidocaine—Back pain—Doxorubicin—urinary bladder cancer	8.62e-05	0.00068	CcSEcCtD
Lidocaine—Confusional state—Methotrexate—urinary bladder cancer	8.47e-05	0.000668	CcSEcCtD
Lidocaine—Loss of consciousness—Epirubicin—urinary bladder cancer	8.47e-05	0.000668	CcSEcCtD
Lidocaine—Anaphylactic shock—Methotrexate—urinary bladder cancer	8.4e-05	0.000663	CcSEcCtD
Lidocaine—Vision blurred—Doxorubicin—urinary bladder cancer	8.4e-05	0.000663	CcSEcCtD
Lidocaine—Convulsion—Epirubicin—urinary bladder cancer	8.35e-05	0.000658	CcSEcCtD
Lidocaine—Nausea—Etoposide—urinary bladder cancer	8.33e-05	0.000657	CcSEcCtD
Lidocaine—Hypertension—Epirubicin—urinary bladder cancer	8.32e-05	0.000656	CcSEcCtD
Lidocaine—Nervous system disorder—Methotrexate—urinary bladder cancer	8.24e-05	0.00065	CcSEcCtD
Lidocaine—Chest pain—Epirubicin—urinary bladder cancer	8.2e-05	0.000647	CcSEcCtD
Lidocaine—Agitation—Doxorubicin—urinary bladder cancer	8.19e-05	0.000646	CcSEcCtD
Lidocaine—Anxiety—Epirubicin—urinary bladder cancer	8.18e-05	0.000645	CcSEcCtD
Lidocaine—Hyperhidrosis—Methotrexate—urinary bladder cancer	8.12e-05	0.000641	CcSEcCtD
Lidocaine—Confusional state—Epirubicin—urinary bladder cancer	7.93e-05	0.000625	CcSEcCtD
Lidocaine—Anaphylactic shock—Epirubicin—urinary bladder cancer	7.86e-05	0.00062	CcSEcCtD
Lidocaine—Oedema—Epirubicin—urinary bladder cancer	7.86e-05	0.00062	CcSEcCtD
Lidocaine—Hypotension—Methotrexate—urinary bladder cancer	7.85e-05	0.000619	CcSEcCtD
Lidocaine—Loss of consciousness—Doxorubicin—urinary bladder cancer	7.84e-05	0.000618	CcSEcCtD
Lidocaine—Shock—Epirubicin—urinary bladder cancer	7.74e-05	0.00061	CcSEcCtD
Lidocaine—Convulsion—Doxorubicin—urinary bladder cancer	7.73e-05	0.000609	CcSEcCtD
Lidocaine—Nervous system disorder—Epirubicin—urinary bladder cancer	7.71e-05	0.000608	CcSEcCtD
Lidocaine—Hypertension—Doxorubicin—urinary bladder cancer	7.7e-05	0.000607	CcSEcCtD
Lidocaine—Hyperhidrosis—Epirubicin—urinary bladder cancer	7.6e-05	0.000599	CcSEcCtD
Lidocaine—Chest pain—Doxorubicin—urinary bladder cancer	7.59e-05	0.000599	CcSEcCtD
Lidocaine—Anxiety—Doxorubicin—urinary bladder cancer	7.56e-05	0.000596	CcSEcCtD
Lidocaine—Paraesthesia—Methotrexate—urinary bladder cancer	7.55e-05	0.000595	CcSEcCtD
Lidocaine—Dyspnoea—Methotrexate—urinary bladder cancer	7.49e-05	0.000591	CcSEcCtD
Lidocaine—Somnolence—Methotrexate—urinary bladder cancer	7.47e-05	0.000589	CcSEcCtD
Lidocaine—Hypotension—Epirubicin—urinary bladder cancer	7.35e-05	0.000579	CcSEcCtD
Lidocaine—Confusional state—Doxorubicin—urinary bladder cancer	7.34e-05	0.000579	CcSEcCtD
Lidocaine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	7.28e-05	0.000574	CcSEcCtD
Lidocaine—Oedema—Doxorubicin—urinary bladder cancer	7.28e-05	0.000574	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	7.26e-05	0.000572	CcSEcCtD
Lidocaine—Pain—Methotrexate—urinary bladder cancer	7.19e-05	0.000567	CcSEcCtD
Lidocaine—Shock—Doxorubicin—urinary bladder cancer	7.16e-05	0.000564	CcSEcCtD
Lidocaine—Nervous system disorder—Doxorubicin—urinary bladder cancer	7.14e-05	0.000563	CcSEcCtD
Lidocaine—Paraesthesia—Epirubicin—urinary bladder cancer	7.06e-05	0.000557	CcSEcCtD
Lidocaine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	7.03e-05	0.000555	CcSEcCtD
Lidocaine—Dyspnoea—Epirubicin—urinary bladder cancer	7.01e-05	0.000553	CcSEcCtD
Lidocaine—Somnolence—Epirubicin—urinary bladder cancer	6.99e-05	0.000551	CcSEcCtD
Lidocaine—Feeling abnormal—Methotrexate—urinary bladder cancer	6.93e-05	0.000546	CcSEcCtD
Lidocaine—Hypotension—Doxorubicin—urinary bladder cancer	6.8e-05	0.000536	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.79e-05	0.000535	CcSEcCtD
Lidocaine—Pain—Epirubicin—urinary bladder cancer	6.73e-05	0.00053	CcSEcCtD
Lidocaine—Urticaria—Methotrexate—urinary bladder cancer	6.68e-05	0.000526	CcSEcCtD
Lidocaine—Paraesthesia—Doxorubicin—urinary bladder cancer	6.53e-05	0.000515	CcSEcCtD
Lidocaine—Dyspnoea—Doxorubicin—urinary bladder cancer	6.49e-05	0.000512	CcSEcCtD
Lidocaine—Feeling abnormal—Epirubicin—urinary bladder cancer	6.48e-05	0.000511	CcSEcCtD
Lidocaine—Somnolence—Doxorubicin—urinary bladder cancer	6.47e-05	0.00051	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	6.28e-05	0.000495	CcSEcCtD
Lidocaine—Urticaria—Epirubicin—urinary bladder cancer	6.25e-05	0.000493	CcSEcCtD
Lidocaine—Pain—Doxorubicin—urinary bladder cancer	6.22e-05	0.000491	CcSEcCtD
Lidocaine—Hypersensitivity—Methotrexate—urinary bladder cancer	6.19e-05	0.000488	CcSEcCtD
Lidocaine—Asthenia—Methotrexate—urinary bladder cancer	6.03e-05	0.000475	CcSEcCtD
Lidocaine—Feeling abnormal—Doxorubicin—urinary bladder cancer	6e-05	0.000473	CcSEcCtD
Lidocaine—Hypersensitivity—Epirubicin—urinary bladder cancer	5.79e-05	0.000457	CcSEcCtD
Lidocaine—Urticaria—Doxorubicin—urinary bladder cancer	5.78e-05	0.000456	CcSEcCtD
Lidocaine—Asthenia—Epirubicin—urinary bladder cancer	5.64e-05	0.000445	CcSEcCtD
Lidocaine—Dizziness—Methotrexate—urinary bladder cancer	5.56e-05	0.000438	CcSEcCtD
Lidocaine—Hypersensitivity—Doxorubicin—urinary bladder cancer	5.36e-05	0.000423	CcSEcCtD
Lidocaine—Vomiting—Methotrexate—urinary bladder cancer	5.34e-05	0.000421	CcSEcCtD
Lidocaine—Rash—Methotrexate—urinary bladder cancer	5.3e-05	0.000418	CcSEcCtD
Lidocaine—Dermatitis—Methotrexate—urinary bladder cancer	5.29e-05	0.000417	CcSEcCtD
Lidocaine—Headache—Methotrexate—urinary bladder cancer	5.26e-05	0.000415	CcSEcCtD
Lidocaine—Asthenia—Doxorubicin—urinary bladder cancer	5.22e-05	0.000412	CcSEcCtD
Lidocaine—Dizziness—Epirubicin—urinary bladder cancer	5.2e-05	0.00041	CcSEcCtD
Lidocaine—Vomiting—Epirubicin—urinary bladder cancer	5e-05	0.000394	CcSEcCtD
Lidocaine—Nausea—Methotrexate—urinary bladder cancer	4.99e-05	0.000394	CcSEcCtD
Lidocaine—Rash—Epirubicin—urinary bladder cancer	4.96e-05	0.000391	CcSEcCtD
Lidocaine—Dermatitis—Epirubicin—urinary bladder cancer	4.95e-05	0.000391	CcSEcCtD
Lidocaine—Headache—Epirubicin—urinary bladder cancer	4.93e-05	0.000388	CcSEcCtD
Lidocaine—Dizziness—Doxorubicin—urinary bladder cancer	4.81e-05	0.000379	CcSEcCtD
Lidocaine—Nausea—Epirubicin—urinary bladder cancer	4.67e-05	0.000368	CcSEcCtD
Lidocaine—Vomiting—Doxorubicin—urinary bladder cancer	4.63e-05	0.000365	CcSEcCtD
Lidocaine—Rash—Doxorubicin—urinary bladder cancer	4.59e-05	0.000362	CcSEcCtD
Lidocaine—Dermatitis—Doxorubicin—urinary bladder cancer	4.58e-05	0.000361	CcSEcCtD
Lidocaine—Headache—Doxorubicin—urinary bladder cancer	4.56e-05	0.000359	CcSEcCtD
Lidocaine—Nausea—Doxorubicin—urinary bladder cancer	4.32e-05	0.000341	CcSEcCtD
Lidocaine—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	1.08e-05	0.000112	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—PTEN—urinary bladder cancer	1.08e-05	0.000112	CbGpPWpGaD
Lidocaine—EGFR—Immune System—FGFR3—urinary bladder cancer	1.08e-05	0.000112	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—EP300—urinary bladder cancer	1.07e-05	0.000111	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.06e-05	0.00011	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.05e-05	0.000109	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.05e-05	0.000109	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.04e-05	0.000108	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—RRM2—urinary bladder cancer	1.04e-05	0.000108	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—SRC—urinary bladder cancer	1.04e-05	0.000108	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	1.04e-05	0.000107	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PPARG—urinary bladder cancer	1.03e-05	0.000106	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—SRC—urinary bladder cancer	1e-05	0.000104	CbGpPWpGaD
Lidocaine—EGFR—Disease—FGFR3—urinary bladder cancer	9.94e-06	0.000103	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	9.91e-06	0.000103	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—CREBBP—urinary bladder cancer	9.87e-06	0.000102	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—TNF—urinary bladder cancer	9.85e-06	0.000102	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	9.83e-06	0.000102	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—KRAS—urinary bladder cancer	9.77e-06	0.000101	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	9.74e-06	0.000101	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	9.65e-06	0.0001	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ENO2—urinary bladder cancer	9.65e-06	0.0001	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—TYMS—urinary bladder cancer	9.64e-06	9.99e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.6e-06	9.95e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—S100B—urinary bladder cancer	9.57e-06	9.92e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	9.53e-06	9.87e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	9.53e-06	9.87e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	9.5e-06	9.85e-05	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	9.38e-06	9.72e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	9.36e-06	9.7e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	9.31e-06	9.65e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—TYMP—urinary bladder cancer	9.29e-06	9.63e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.22e-06	9.56e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	9.2e-06	9.54e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—NQO1—urinary bladder cancer	9.19e-06	9.53e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CREBBP—urinary bladder cancer	9.17e-06	9.5e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—GPX1—urinary bladder cancer	9.12e-06	9.45e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CDH1—urinary bladder cancer	9.1e-06	9.43e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—RRM2—urinary bladder cancer	9.08e-06	9.41e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—RHOA—urinary bladder cancer	9.08e-06	9.41e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—NQO1—urinary bladder cancer	8.98e-06	9.31e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	8.97e-06	9.29e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	8.96e-06	9.28e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	8.92e-06	9.24e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—TYMS—urinary bladder cancer	8.83e-06	9.16e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	8.73e-06	9.05e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	8.73e-06	9.05e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—KRAS—urinary bladder cancer	8.63e-06	8.94e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NCOR1—urinary bladder cancer	8.61e-06	8.92e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	8.56e-06	8.87e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	8.48e-06	8.79e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—CREBBP—urinary bladder cancer	8.46e-06	8.77e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	8.42e-06	8.73e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ENO2—urinary bladder cancer	8.41e-06	8.72e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—HPGDS—urinary bladder cancer	8.41e-06	8.72e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—NAT2—urinary bladder cancer	8.4e-06	8.7e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—GPX1—urinary bladder cancer	8.36e-06	8.67e-05	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—HRAS—urinary bladder cancer	8.31e-06	8.61e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—KRAS—urinary bladder cancer	8.29e-06	8.59e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	8.21e-06	8.51e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GSTT1—urinary bladder cancer	8.16e-06	8.45e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PTGS2—urinary bladder cancer	8.08e-06	8.37e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CXCL8—urinary bladder cancer	7.97e-06	8.26e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	7.93e-06	8.21e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	7.93e-06	8.21e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	7.86e-06	8.14e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	7.86e-06	8.14e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	7.81e-06	8.1e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—NQO1—urinary bladder cancer	7.78e-06	8.07e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	7.72e-06	8e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	7.69e-06	7.97e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—ERBB2—urinary bladder cancer	7.68e-06	7.96e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	7.67e-06	7.95e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—RHOA—urinary bladder cancer	7.66e-06	7.93e-05	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	7.64e-06	7.92e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	7.62e-06	7.9e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—IL2—urinary bladder cancer	7.61e-06	7.89e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TERT—urinary bladder cancer	7.59e-06	7.86e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.55e-06	7.83e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	7.5e-06	7.78e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	7.49e-06	7.77e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—HRAS—urinary bladder cancer	7.34e-06	7.6e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—RRM2—urinary bladder cancer	7.25e-06	7.51e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	7.17e-06	7.43e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—TYMS—urinary bladder cancer	7.13e-06	7.39e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—ERBB2—urinary bladder cancer	7.09e-06	7.35e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	7.05e-06	7.3e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	7.05e-06	7.3e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PTEN—urinary bladder cancer	7.05e-06	7.3e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—HRAS—urinary bladder cancer	7.04e-06	7.3e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—TYMS—urinary bladder cancer	6.97e-06	7.22e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—FGFR3—urinary bladder cancer	6.96e-06	7.22e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL2—urinary bladder cancer	6.96e-06	7.21e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTGS2—urinary bladder cancer	6.93e-06	7.18e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	6.89e-06	7.14e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	6.89e-06	7.14e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PPARG—urinary bladder cancer	6.83e-06	7.08e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—NQO1—urinary bladder cancer	6.78e-06	7.03e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—ESR1—urinary bladder cancer	6.76e-06	7.01e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—GPX1—urinary bladder cancer	6.75e-06	6.99e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—EP300—urinary bladder cancer	6.72e-06	6.96e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	6.71e-06	6.96e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ENO2—urinary bladder cancer	6.71e-06	6.96e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.68e-06	6.92e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	6.62e-06	6.87e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GPX1—urinary bladder cancer	6.59e-06	6.83e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.58e-06	6.82e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CDKN1A—urinary bladder cancer	6.56e-06	6.8e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	6.56e-06	6.8e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PTEN—urinary bladder cancer	6.55e-06	6.78e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	6.51e-06	6.75e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	6.49e-06	6.73e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	6.48e-06	6.72e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	6.47e-06	6.71e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.41e-06	6.65e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	6.39e-06	6.62e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	6.33e-06	6.56e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.28e-06	6.51e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PPARG—urinary bladder cancer	6.26e-06	6.49e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—EP300—urinary bladder cancer	6.24e-06	6.47e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	6.23e-06	6.45e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.15e-06	6.37e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	6.09e-06	6.31e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—SRC—urinary bladder cancer	6.07e-06	6.29e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—CDKN1A—urinary bladder cancer	6.06e-06	6.28e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTEN—urinary bladder cancer	6.04e-06	6.26e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—TYMS—urinary bladder cancer	6.03e-06	6.25e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	6.01e-06	6.23e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	5.96e-06	6.18e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	5.96e-06	6.18e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CREBBP—urinary bladder cancer	5.93e-06	6.14e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IGF1—urinary bladder cancer	5.85e-06	6.07e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—EP300—urinary bladder cancer	5.76e-06	5.97e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GPX1—urinary bladder cancer	5.71e-06	5.92e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	5.65e-06	5.86e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	5.61e-06	5.81e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—SRC—urinary bladder cancer	5.61e-06	5.81e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	5.6e-06	5.8e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—KRAS—urinary bladder cancer	5.5e-06	5.7e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	5.41e-06	5.61e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	5.37e-06	5.57e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—RHOA—urinary bladder cancer	5.36e-06	5.56e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.36e-06	5.55e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	5.33e-06	5.52e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	5.28e-06	5.47e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	5.27e-06	5.46e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—TYMS—urinary bladder cancer	5.26e-06	5.45e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.25e-06	5.44e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	5.2e-06	5.39e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	5.2e-06	5.39e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	5.18e-06	5.37e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	5.18e-06	5.37e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.11e-06	5.3e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PPARG—urinary bladder cancer	5.05e-06	5.23e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—KRAS—urinary bladder cancer	5.03e-06	5.21e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	5.03e-06	5.21e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MYC—urinary bladder cancer	5.02e-06	5.21e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GPX1—urinary bladder cancer	4.98e-06	5.16e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—ERBB2—urinary bladder cancer	4.96e-06	5.14e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	4.95e-06	5.13e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PPARG—urinary bladder cancer	4.94e-06	5.11e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	4.92e-06	5.1e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	4.91e-06	5.09e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	4.9e-06	5.07e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	4.9e-06	5.07e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	4.89e-06	5.06e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	4.85e-06	5.03e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	4.85e-06	5.03e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	4.85e-06	5.03e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	4.74e-06	4.91e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CXCL8—urinary bladder cancer	4.71e-06	4.88e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	4.69e-06	4.86e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTEN—urinary bladder cancer	4.68e-06	4.85e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—HRAS—urinary bladder cancer	4.68e-06	4.85e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	4.65e-06	4.82e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—KRAS—urinary bladder cancer	4.64e-06	4.81e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	4.6e-06	4.77e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	4.59e-06	4.76e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.58e-06	4.75e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	4.56e-06	4.73e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	4.51e-06	4.68e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL2—urinary bladder cancer	4.5e-06	4.66e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—EP300—urinary bladder cancer	4.47e-06	4.63e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CCND1—urinary bladder cancer	4.39e-06	4.54e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.37e-06	4.53e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	4.33e-06	4.49e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTEN—urinary bladder cancer	4.29e-06	4.45e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	4.29e-06	4.45e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PPARG—urinary bladder cancer	4.27e-06	4.43e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HRAS—urinary bladder cancer	4.27e-06	4.43e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MMP9—urinary bladder cancer	4.26e-06	4.41e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CDKN1A—urinary bladder cancer	4.24e-06	4.4e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PTEN—urinary bladder cancer	4.23e-06	4.39e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	4.2e-06	4.35e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	4.18e-06	4.33e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	4.15e-06	4.3e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	4.15e-06	4.3e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	4.11e-06	4.26e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—EP300—urinary bladder cancer	4.09e-06	4.24e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—EP300—urinary bladder cancer	4.04e-06	4.18e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	3.97e-06	4.12e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	3.97e-06	4.12e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—HRAS—urinary bladder cancer	3.94e-06	4.09e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—SRC—urinary bladder cancer	3.93e-06	4.07e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	3.9e-06	4.04e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	3.88e-06	4.02e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PPARG—urinary bladder cancer	3.72e-06	3.86e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	3.67e-06	3.8e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	3.58e-06	3.71e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MYC—urinary bladder cancer	3.52e-06	3.65e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	3.51e-06	3.64e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	3.48e-06	3.61e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	3.48e-06	3.61e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTEN—urinary bladder cancer	3.46e-06	3.59e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTEN—urinary bladder cancer	3.39e-06	3.51e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	3.37e-06	3.49e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	3.36e-06	3.48e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	3.34e-06	3.46e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—EP300—urinary bladder cancer	3.3e-06	3.42e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KRAS—urinary bladder cancer	3.25e-06	3.37e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.24e-06	3.36e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—EP300—urinary bladder cancer	3.23e-06	3.35e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	3.2e-06	3.32e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	3.2e-06	3.32e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.07e-06	3.18e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.01e-06	3.12e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	2.97e-06	3.08e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTEN—urinary bladder cancer	2.93e-06	3.04e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	2.93e-06	3.04e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TP53—urinary bladder cancer	2.89e-06	2.99e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	2.86e-06	2.96e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.83e-06	2.93e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—EP300—urinary bladder cancer	2.8e-06	2.9e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—HRAS—urinary bladder cancer	2.76e-06	2.86e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.76e-06	2.86e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	2.74e-06	2.84e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.55e-06	2.65e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—EP300—urinary bladder cancer	2.44e-06	2.53e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.41e-06	2.5e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.39e-06	2.47e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	2.34e-06	2.42e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.3e-06	2.38e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.29e-06	2.38e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.28e-06	2.36e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.2e-06	2.28e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	2.04e-06	2.11e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.95e-06	2.02e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.8e-06	1.87e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.57e-06	1.63e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.5e-06	1.56e-05	CbGpPWpGaD
